Abstracts tagged "Biomarkers and psoriatic arthritis"

Abstract Number: 651 • 2017 ACR/ARHP Annual Meeting
Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment
Rohan Machhar¹, Justine (Yang) Ye¹, Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. miRNA’s are small non coding RNAs whose main function, at a post…
Abstract Number: 1738 • 2015 ACR/ARHP Annual Meeting
Assessing the Validity of the Multi-Biomarker Disease Activity Assay in Patients with Psoriatic Arthritis
Tristan Boyd¹, Doquyen H. Huynh¹, P. Scott Eastman², Ferhan Qureshi³, Eric H. Sasso⁴, Rebecca J. Bolce⁴, Joshua Hillman⁵, David L. Boyle⁶ and Arthur Kavanaugh⁷, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²Crescendo Bioscience, South San Francisco, CA, ³Crescendo Bioscience, Inc., South San Francisco, CA, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁷University of California, San Diego School of Medicine, LaJolla, CA
Background/Purpose: Considerable heterogeneity across clinical domains of psoriatic arthritis (PsA) can make assessment of disease activity challenging. As a result, there has been interest in…
Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting
Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
Abstract Number: 2501 • 2013 ACR/ARHP Annual Meeting
Validation Of Gene Expression Biomarkers Of Psoriatic Arthritis
Fatima Abji¹, Remy Pollock¹, Fawnda Pellett², Kun Liang³, Vinod Chandran² and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative immune mediated arthritis that develops in about a third of patients with cutaneous psoriasis (PsC). The cellular pathways…
Abstract Number: 534 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Gene Expression Profiling Of Psoriatic Arthritis Patient
Bidisha Dasgupta, Yauheniya Cherkas, Sarah Lamberth and Carrie Brodmerkel, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Although PsA is heterogeneous and shows signs of rheumatoid arthritis (RA) and psoriasis (PsO), genetic studies indicate that PsA is a distinct disease with…
Abstract Number: 1350 • 2012 ACR/ARHP Annual Meeting
Inflammatory Biomarkers in Psoriatic Arthritis
Ibrahim AlHomood¹, Arane Thavaneswaran¹, D. D. Gladman² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that may progress rapidly and result in joint damage and disability. The aim of this study was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].